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Abstract
Background: Immunoglobulin G4-related disease (IgG4-RD) is a fibroinflammatory disorder that may involve single
or multiple organs. Biopsy-proven lung involvement of this disease is occasionally reported, but not well understood.
Methods: Patients with the diagnosis of biopsy-proven IgG4-related lung disease (IgG4-RLD) from Peking Union Medical
College Hospital between January 2011 and July 2015 were retrospectively analyzed. Age, sex, clinical symptoms,
laboratory findings, pulmonary function test results, chest CT tests, positron emission tomography (PET) examinations,
treatments and prognoses were retrieved from medical records and analyzed.
Results: Seventeen patients were included in this study (mean age: 44.8 ± 15.0 years). Ten patients were diagnosed via
surgery, and 7 patients were diagnosed via percutaneous transthoracic core-needle lung biopsy. Extrapulmonary
involvement was observed in only one patient. The clinical symptoms included cough, fever, dyspnea, chest pain
and hemoptysis. The serum IgG4 concentration was elevated in 7/13 patients (mean: 1955 ± 1968 mg/L). The chest CT
findings included mainly nodules and masses with spiculated borders, alveolar consolidations with air bronchograms,
and ground glass opacities with or without reticular opacities. PET scans indicated increased standardized uptake values,
and 7/8 patients were correctly diagnosed with benign inflammation. Corticosteroids and immunosuppressants were
administered to 14/17 patients and effectively alleviated the disease.
Conclusions: In biopsy-proven IgG4-RLD, a normal serum IgG4 concentration is commonly seen, while extrapulmonary
involvement is infrequent. Alveolar consolidation with air bronchograms is an important imaging finding of IgG4-RLD,
which has not been emphasized before.
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Background
Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is
a recently recognized fibroinflammatory condition that
is characterized by tumefactive involvement of single or
multiple organs, marked lymphoplasmacytic infiltrates
and fibrosis with abundant IgG4-positive plasma cells.
IgG4-RD is often associated with elevated serum IgG4
concentrations [1]. Since Hamano and colleagues (2001)
first reported elevated serum IgG4 concentration in
autoimmune pancreatitis [2], IgG4-RD has been diag-
nosed in virtually every organ system.
IgG4-RD lung involvement was first reported in 2004
by Taniguchi and colleagues in a patient with interstitial
pneumonia, autoimmune pancreatitis and IgG4-positive
plasma cells in the interstitium [3]. Although lung in-
volvement has been reported in many IgG4-RD studies
since then, the majority of them were not confirmed by
lung biopsies. To our knowledge, the only two biopsy-
proven studies of IgG4-related lung disease (IgG4-RLD)
were retrospective and performed in Japan [4, 5].
However, both studies included patients diagnosed via
transbronchial lung biopsy. In our opinion, the lung
specimen from transbronchial lung biopsy is too small
to make a pathological diagnosis of IgG4-RLD. There-
fore, we made this study including 17 cases of biopsy-
proven IgG4-RLD, with specimens obtained via thora-
cotomy, video-assisted thoracoscopic surgery (VATS) or
percutaneous transthoracic core-needle lung biopsy, to
better understand this rare disease.
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Patients suspected of IgG4-RLD at Peking Union Medical
College Hospital from January 2011 to July 2015 were in-
vestigated in October 2015. Only patients who fulfilled the
following inclusion criteria were included in this study: (i)
pulmonary parenchymal abnormality via chest computed
tomography (CT) scanning; (ii) histopathological examin-
ation of a lung specimen obtained by thoracotomy, VATS
or a percutaneous transthoracic CT-guided core-needle
lung biopsy that demonstrated the features of IgG4-RD,
including (a) marked lymphocyte and plasmacyte infiltra-
tion and fibrosis; and (b) a ratio of IgG4+/IgG+ cells >
40 % and/or > 10 IgG4+ plasma cells/HPF [6]; and (iii)
histopathological examination that precluded other
diseases, such as Castleman’s disease, lymphoma, or
lung cancer.
Patients were defined as definite, probable or possible
IgG4-RLD according to the 2011 comprehensive diag-
nostic criteria for IgG4-RD [6]. In order to define every
patient, patients without serum IgG4 results were con-
sidered to have a normal serum IgG4 concentration.
Data were collected by medical records, telephone and
letters. The following data were retrieved for analysis:
age, sex, clinical symptoms, laboratory findings, pul-
monary function test results, chest CT tests, 18F-fluoro-
deoxyglucose positron emission tomography (18F-FDG
PET) examinations, treatments and prognoses.
The study was approved by the Ethical Committee of
Peking Union Medical College Hospital (Reference num-
ber: S-K038). Informed consent for participation and
publication was obtained from all patients at the time of
diagnosis or follow-up. If the patient was dead or uncon-
tactable, the informed consent was obtained from their
families.
Statistical analysis
Data were analyzed using the Statistical Package for the
Social Sciences (SPSS, version 19.0 software) (SPSS Inc.,
Chicago, Illinois, USA). Mean values were expressed as
values + standard deviations.
Results
General characteristics and extrapulmonary involvement
A total of 19 Chinese patients fulfilled the inclusion cri-
teria (i) and (ii) and IgG4-RLD was suspected. However,
2 patients were excluded due to other malignant diseases
that were pathologically discovered at the time of diag-
nosis. Therefore, 17 IgG4-RLD patients were included in
this study. The inclusion procedure is illustrated in Fig. 1.
According to the 2011 comprehensive diagnostic cri-
teria, 7 (41.2 %) and 10 (58.8 %) patients were diagnosed
with definite and probable IgG4-RLD respectively.
Among the 17 included patients, 4 patients were
initially diagnosed with nonspecific interstitial pneumo-
nia (NSIP) in the 2000s. However, a pathological review
performed in 2012 confirmed a diagnosis of IgG4-RLD
[7]. Two patients were diagnosed with primary Sjogren
syndrome and IgG4-RLD simultaneously. IgG4-RLD was
considered to be connective tissue disease (CTD) - related
in both patients.





15 patients were 
diagnosed with idiopathic 
IgG4-RLD
2 patients were diagnosed 
2 patients were excluded due to separate  
pathological confirmations of Castleman’s 
patients were diagnosed with biopsy-proven  
with CTD-related IgG4-RLD
Fig. 1 Flow diagram of the diagnostic process for IgG4-related lung disease
Sun et al. BMC Pulmonary Medicine  (2016) 16:20 Page 2 of 7
There were nearly twice as many female patients. The
patient age ranged from 18 to 71 years (mean age:
44.8 years). Four patients had a history of smoking (range:
16 to 50 pack-years). Comorbidity was noted in 11 pa-
tients. Except for primary Sjogren syndrome, which was
diagnosed at the same time as IgG4-RLD, the other co-
morbidities were all previously diagnosed (Table 1).
Out of 17 biopsy-proven IgG4-RLD patients, extrapul-
monary involvement was proven in only one patient
with uveitis and biopsy-proven IgG4-related mastoiditis,
with the help of CT and PET (lymph node less than
1 cm in diameter was considered nonspecific).
Clinical symptoms and laboratory findings of IgG4-RLD
Most patients had mild or severe clinical symptoms
(Table 1), but two patients were asymptomatic and pul-
monary abnormalities were discovered accidently. The
time from onset of the initial symptoms to diagnosis
ranged from 1 month to 7 years, and the median interval
time was 8 months.
Main laboratory findings are listed in Table 1. Serum
IgG4 concentration was examined in all patients except
for the 4 patients initially diagnosed with NSIP. Serum
IgG4 level ranged from 77 to 7490 mg/L with a mean
level of 1955 ± 1968 mg/L. Further examination revealed
that the WBC, ESR and CRP levels were higher in pa-
tients with fever compared to patients without fever
[WBC (×109/L), 11.5 vs 8.06; ESR (mm/h), 72.7 vs 29.7;
CRP (mg/dL), 85.7 vs 13.4], and patients with high serum
IgG4 concentrations were more prone to have fever, com-
pared with those with normal serum IgG4 concentrations
(5/7 vs 1/6).
Chest CT, PET and pulmonary function test results for
patients with IgG4-RLD
Chest CT findings and pulmonary function test results
are listed in Table 1. Multifocal or diffuse lesions were
observed in 13 (76.5 %) patients, and 4 (23.5 %) patients
presented with local lesions. Nodules and masses with
spiculated borders (Fig. 2a), alveolar consolidations with
air bronchograms (Fig. 2b), ground glass opacities with
or without reticular opacities (Fig. 2c, d), and hilar or
mediastinal lymphadenopathy (lymph node longer than
1 cm in diameter) were the most common CT findings.
Eight patients received 18F-FDG PET examinations.
The maximum standard uptake values (SUVs) ranged
from 4.0 to 11.8 (7.4 ± 3.0). Benign inflammation was
diagnosed in 7/8 (87.5 %) patients, and malignancy
was suspected in only 1/8 (12.5 %) patient. During
evaluation, PET showed a high SUV in sublingual
gland in one patient, however, biopsy excluded IgG4-
RD involvement.




Male : Female 1 : 1.83
Age (years) 44.8 ± 15.0 (18–71)
History of smoking 4/17 (23.5 %)
Comorbidity
Allergy 3/17
Primary Sjogren syndrome 2/17
Healed pulmonary tuberculosis 2/17
Chronic gastritis 1/17
Diabetes mellitus 1/17






Cough 11/17 (64.7 %)
Fever 7/17 (41.2 %)
Dyspnea 5/17 (29.4 %)
Chest pain 4/17 (23.5 %)
Hemoptysis 2/17 (11.8 %)
Asymptomatic 2/17 (11.8 %)
Laboratory findings
White blood cell count > 10 × 109/L 7/17 (41.2 %)
ESR > 20 mm/h 11/17 (64.7 %)
CRP > 5 mg/L 8/17 (47.1 %)
IgG > 17 g/L 11/15 (73.3 %)
IgG4 > 1350 mg/L 7/13 (53.8 %)
IgG4/IgG > 8 % 5/13 (38.5 %)
tIgE > 100 IU/mL 5/8 (62.5 %)
ANA ≥ 1:80 3/16 (18.8 %)
Chest CT findings
Nodules and masses with spiculated borders 8/17 (47.1 %)
Alveolar consolidations with air bronchograms 5/17 (29.4 %)
Ground glass opacities ± reticular opacities 6/17 (35.3 %)
Hilar or mediastinal lymphadenopathy 5/17 (29.4 %)
Thickening of the bronchovasular bundles 2/17 (11.8 %)
Thickening of the interlobular septa 2/17 (11.8 %)
Pulmonary function test
FEV1/FVC < 70 % 1/9 (11.1 %)
TLC% < 80 % 3/7 (42.9 %)
DLCO% < 80 % 8/8 (100 %)
ESR erythrocyte sedimentation rate, CRP C-reactive protein, ANA antinuclear
antibody, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, DLCO
diffusing capacity of the lung for carbon monoxide
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Histological findings for IgG4-RLD
A wedge resection or lobectomy was performed in 8 pa-
tients using VATS and 2 patients using posterolateral
thoracotomies. Seven other patients were diagnosed
using a CT-guided core-needle lung biopsy. Three patients
first received a transthoracic core-needle lung biopsy and
eventually underwent VATS or posterolateral thoracotomy
due to nonspecific results.
Histopathologically, all specimens showed diffuse lym-
phoplasmacytic infiltration and irregular fibrosis within
the peribronchial and perivascular connective tissues
(Fig. 3c). The alveolar structure was severely distorted
and obliterative phlebitis was a common presentation
in nodule or mass lesions (Fig. 3a, b). The IgG4+ cell
count was increased in all patients (Fig. 3d), and the
ratio of IgG4+/IgG+ cells was also increased. As part
of the inclusion criteria, malignancy was precluded by
morphological and immunohistochemical examinations.
Treatment and prognosis
Prednisone (20–50 mg per day) or an equivalent dose of
another glucocorticoid was administered to 14 patients.
Immunosuppressive agents were administered in 6 of
theses patients, including cyclophosphamide (4 patients),
azathioprine (1 patient) and mycophenolate mofetil
(1 patient). During the follow-up (1 month to 8 years,
median time: 18 months), clinical remission was achieved
in all patients. However, relapse was observed in 4 patients
during glucocorticoid tapering (Fig. 4). Persistent pul-
monary abnormalities (shrunken, but similar to the
initial manifestation) were observed in the 11 patients
who were followed for more than 6 months.
Three patients with mild and stable lung lesions did
not receive any corticosteroid or immunosuppressant, and
all of them were stable (confirmed by chest CT) during
the mean follow-up time of 3 years.
Death was observed in one patient, who died of respira-
tory failure caused by relapse of IgG4-related interstitial
lung disease after glucocorticoid tapering.
Discussion
As a newly recognized disease, IgG4-RLD is still not well
understood. In this retrospective study, we analyzed 17
cases of biopsy-proven IgG4-RLD in Chinese to identify
the characteristics of this rare disease.
It is still unclear how often lung involvement occurs in
patients with IgG4-RD. A retrospective study of 90 pa-
tients with autoimmune pancreatitis revealed that 54 %
of patients had lung lesions [8], but another study of 116
patients with biopsy-proven IgG4-RD revealed that biopsy-
proven IgG4-RLD accounted for only approximately 10 %
of the cases [9]. The difference might be explained by fol-
lowing reasons: (i) In IgG4-RD patients with multiple or-
gans involvement, lung specimen is less probably obtained
Fig. 2 Different manifestations of IgG4-related lung disease via chest computed tomography (CT) scans. a Multiple nodules and masses with
variable sizes are shown in both lungs via CT scans. Peribronchovascular thickening and thickened interlobular/interlobar septa were also noted.
b Alveolar consolidations with air bronchograms in the right upper lobe. c Multiple ground glass opacities without reticular opacity. d Ground
glass opacities with reticular opacities and early honeycombing
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because it is more invasive; (ii) Infection, aspiration pneu-
monia, pulmonary congestion, etc., also contribute to lung
lesions in IgG4-RD patients, which might be mis-
diagnosed as lung involvement. Therefore, IgG4-RLD
should be cautiously diagnosed without a pathological
confirmation.
Compared with typical IgG4-RD involving two or more
organs, this study showed uncommon extrapulmonary
involvement in biopsy-proven IgG4-RLD, even with the
help of PET. Although selection bias exists because
patients with only lung involvement are more prone to re-
ceive a lung bi,opsy, this association indicates that lung
involvement is probably over-estimated in IgG4-RD
patients. Thus, pathological confirmation seems crucial
for the diagnosis of IgG4-RLD.
The etiology of IgG4-RLD is still unknown. Auto-
immunity is currently considered as the main pathogenic
mechanism [10]. Two patients were simultaneously
Fig. 3 a Chest computed tomography scan in a 55-year-old man shows a spiculated mass in the right middle lobe. b Histopathological specimen
obtained from this patient shows distorted alveolar structures and thickened pleura. c Diffuse lymphoplasmocytic infiltrates and fibrosis are observed
at high magnification (H&E; ×100). d An increased IgG4+ cell count is identified (IgG4 immunostaining; ×100)
17 Biopsy-proven IgG4-RLD 
patients
11 patients treated with 
glucocorticoid
7 patients keep stable
4 patients relapse during 
glucocorticoid tapering
3 patients added with 
immunosuppressant 
(stable) 
1 patient dies of 
respiratory failure




3 mild patients NOT 
treated with glucocorticoid 
or immunosuppressant 
(stable)
Fig. 4 Treatment and prognosis of 17 patients with IgG4-related lung disease
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diagnosed with primary Sjogren syndrome in this study,
proving the relationship between IgG4-RLD and CTDs.
An antibody against plasminogenbinding protein of Heli-
cobacter pylori has been identified in more than 90 % of
patients with autoimmune pancreatitis [11], proposing
that infectious agents may play a role in the pathogenesis
of IgG4-RD. But in our study, the association between
IgG4-RLD and infection was not identified.
The clinical symptoms of IgG4-RLD depend on the
lesion locations and are usually nonspecific [12]. In
our study, cough, dyspnea, chest pain and hemoptysis
were the primary respiratory symptoms. Fever was ob-
served in nearly half of the patients in this study indi-
cating that constitutional symptoms are not as rare as
previously thought [13]. Although asymptomatic pa-
tients were also noted in our study, this phenomenon
was not as common as reported in a previous Japanese
study [4].
One study of IgG4-RD patients demonstrated that serum
IgG4 concentrations > 1350 mg/L and serum IgG4/IgG ra-
tios > 8 % had a sensitivity of 97.0 and 95.5 %, respectively
[14]. However, in our study, the above criteria had a sensi-
tivity of only 53.8 and 38.5 %, respectively, in IgG4-RLD
patients. Serum IgG4 concentrations tend to be higher in
patients with multiple organ involvement [15]. Most pa-
tients in this study had only lung involvement, which may
explain the discrepancy. Therefore, it is not appropriate to
exclude a diagnosis of IgG4-RLD due to a normal serum
IgG4 concentration. Inflammatory marker concentrations
are higher in IgG4-RLD patients with fever, suggesting that
constitutional symptoms are associated with disease se-
verity. This phenomenon has been previously reported
by our team [16]. More aggressive treatment is usually
necessary in these patients.
Inoue and colleagues summarized four patterns of CT
findings: solid nodular, round-shaped ground glass opa-
city, alveolar interstitial, and bronchoalveolar [17]. How-
ever, in our study, lobar or segmental consolidation was
commonly seen. Ground glass opacity was patchy or dif-
fuse. A bronchoalveolar manifestation was usually mixed
with other more prominent patterns. Therefore, we
prefer the following categories based on the main mani-
festation: (i) nodule or mass with spiculated margins; (ii)
lobar or segmental consolidation with air bronchograms;
(iii) ground glass opacity; (iv) alveolar interstitial; and (v)
bronchovascular. However, a mixed pattern is commonly
seen in IgG4-RLD patients. Mediastinal and/or hilar
lymphadenopathy have been described in 40 to 90 % of
patients with IgG4-RD in literature [13], however, a
lower rate of mediastinal or hilar lymph node involve-
ment is found in this study, which may be explained by
the reason that a restricted definition of lymphadenop-
athy is applied in this study, and might be associated
with only one organ involvement in most cases.
The use of 18F-FDG PET uncovers more organ in-
volvement than conventional evaluations in IgG4-RD
patients [18]. In IgG4-RD patients with involvement of
two or more organs detected by PET, lung involvement
occurs in approximately 25 % of cases [18, 19]. However,
abnormal uptake is not always associated with IgG4-RD
involvement [19], as demonstrated in our study. There-
fore, the explanation of a high SUV should be cautious
in IgG4-RD patients.
Although lung tissue obtained via a less-invasive, CT-
guided, transthoracic core-needle biopsy is convenient, it
failed to yield a definitive diagnosis in about one third of
patients in this study. Thoracotomy or VATS can obtain
more lung tissue, and are usually required to make a
pathological diagnosis of IgG4-RLD. Transbronchial
cryobiopsy is a new technique that allow to obtain larger
and more qualified specimen than forceps biopsy. The
use of cryobiopsy in diagnosing interstitial lung disease
has been proved to be proper and promising [20, 21].
However, the value of cryobiopsy in IgG4-RLD is still to
be investigated.
To treat IgG4-RLD, corticosteroids are still the corner-
stone therapy. The exact regimen for corticosteroids is
still not detailed, but a regimen similar to extrapulmon-
ary IgG4-RD therapy, such as during autoimmune pan-
creatitis, is recommended [1]. In this study, all patients
treated with steroids achieved remission, which con-
firmed the effectiveness of steroids for IgG4-RLD pa-
tients. Data regarding the use of immunosuppressants
for IgG4-RLD is still sparse. Limited data and our study
demonstrated positive results. Self-limitation has been
occasionally observed in some IgG4-RLD patients [22],
and was also observed in our study. We recommend
medical treatment in most patients. Only some specific
patients can watch and wait, and long-term follow-ups
are necessary.
The value of this study is limited by the small number
of included patients. Our study show that although
IgG4-RLD and typical IgG4-RD share common features,
IgG4-RLD has its own distinct characteristics.
Conclusions
Biopsy-proven IgG4-RLD is different in many ways from
typical IgG4-RD. In biopsy-proven IgG4-RLD, a normal
serum IgG4 concentration is commonly seen, while
extrapulmonary involvement is infrequent. Alveolar con-
solidation with air bronchograms is an important im-
aging finding of IgG4-RLD, which has not been
emphasized before.
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